Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Average Recommendation of “Reduce” from Analysts

Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) have received an average recommendation of “Reduce” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $4.77.

TMCI has been the subject of a number of recent analyst reports. Stifel Nicolaus decreased their price target on shares of Treace Medical Concepts from $5.00 to $3.00 and set a “hold” rating for the company in a report on Wednesday, January 7th. Truist Financial decreased their price target on shares of Treace Medical Concepts from $4.00 to $3.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Lake Street Capital decreased their price target on shares of Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating for the company in a report on Monday, March 2nd. Wall Street Zen cut shares of Treace Medical Concepts from a “hold” rating to a “sell” rating in a report on Tuesday, March 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Treace Medical Concepts in a report on Wednesday, January 21st.

Institutional Investors Weigh In On Treace Medical Concepts

Several hedge funds have recently made changes to their positions in the stock. Invesco Ltd. lifted its stake in shares of Treace Medical Concepts by 18.6% in the second quarter. Invesco Ltd. now owns 15,051 shares of the company’s stock valued at $88,000 after buying an additional 2,362 shares during the period. Osaic Holdings Inc. lifted its stake in shares of Treace Medical Concepts by 328.3% in the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock valued at $28,000 after buying an additional 3,674 shares during the period. Parkman Healthcare Partners LLC lifted its stake in shares of Treace Medical Concepts by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 847,675 shares of the company’s stock valued at $5,688,000 after buying an additional 3,677 shares during the period. Barclays PLC lifted its stake in shares of Treace Medical Concepts by 7.4% in the fourth quarter. Barclays PLC now owns 87,664 shares of the company’s stock valued at $215,000 after buying an additional 6,077 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of Treace Medical Concepts by 5.1% in the second quarter. BNP Paribas Financial Markets now owns 162,976 shares of the company’s stock valued at $958,000 after buying an additional 7,898 shares during the period. Institutional investors own 84.08% of the company’s stock.

Treace Medical Concepts Trading Down 6.9%

Shares of NASDAQ:TMCI opened at $1.34 on Wednesday. The company has a current ratio of 4.31, a quick ratio of 3.13 and a debt-to-equity ratio of 0.64. Treace Medical Concepts has a 1 year low of $1.17 and a 1 year high of $7.96. The firm has a fifty day moving average price of $1.69 and a 200 day moving average price of $3.28. The stock has a market capitalization of $86.55 million, a PE ratio of -1.43 and a beta of 0.87.

Treace Medical Concepts (NASDAQ:TMCI) last released its quarterly earnings results on Friday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.15). Treace Medical Concepts had a negative net margin of 27.74% and a negative return on equity of 59.91%. The company had revenue of $62.52 million during the quarter, compared to analysts’ expectations of $61.76 million. Analysts expect that Treace Medical Concepts will post -0.92 EPS for the current fiscal year.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.